CD8A and neoplasm: In patients with TMB-H tumors, the high expression levels of neoantigens recognized by activated CD8+ T cells after PD-1 blockade can result in the targeted killing of tumor cells, leading to a better response than in patients with low TMB (TMB-L) tumors (12, 13).